Cognitive and behavioral features in atypical parkinsonian syndromes

Introduction Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA), corticobasal degeneration (CBD) and dementia with Lewy Bodies (DLB) are included in atypical parkinsonisms (AP) and they typically involve multisystem degeneration. Defining the neuropsychological profiles is important for a detailed intra-AP framework to identify phenotypes and for characterization of patients, but there are few studies which specifically analyz the neuropsychological and behavioral profiles of AP. Objectives From November 2016 to September 2019, at the University Hospital of Salerno and in collaboration, where necessary, with other Italian centers, data collection and processing work was carried out on a sample of healthy subjects (HC) and patients with movement disorders, divided into patients with Parkinson's disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) and CorticoBasal Syndrome (CBS). Specific work objectives were: 1) investigation of the neuropsychological and behavioral profile of patients with atypical parkinsonism, divided according to their respective clinical phenotypes; 2) investigation of the evolution over time of the neuropsychological and behavioral profile of patients with atypical parkinsonism; 3) identification and characterization of the alteration of global cognitive state, of mild cognitive impairment- single domain (MCI-sd), of mild cognitive impairment - multiple domain (MCI-md) and of normal cognition (NC) of patients with atypical parkinsonism; 4) comparison of neuropsychological and behavioral aspects in healthy subjects and patients with Parkinson's disease; intra-group comparison of the neuropsychological profile between PSP- Cortico Basal Syndrome phenotype and CBS and MSA-Parkinsonian and cerebellar phenotypes; 5) validation of a new language screening battery for neurodegenerative diseases; 6) investigation of language domain in the sample of patients with PSP and MSA by clinical use of the new battery for neurodegenerative diseases;.. [edited by Author]